Hot Life Science Investor Mandate 9: European PE Invests in Drug Development, Diagnostics, and Medical Devices

26 Nov

A private equity firm based in Paris, France has €400M AUM and looks to invest in venture stages in the life sciences – seed to later phases. The firm mainly provides equity financing and may provide convertible loans as follow-on investments. The firm typically makes an initial investment of €2-3M and €5-8M over the life of the investment. The firm only invests in European-based companies. The firm is actively seeking new investment opportunities.

The firm is opportunistic in the life sciences. The firm focuses on drug development, diagnostics, and medical devices.  The firm is agnostic in terms of subsectors and indications. The firm prefers companies with a portfolio of 2-3 products. The firm generally looks for therapeutic companies with products that are in the pre to late clinical phases. Currently, the firm is active in many subsectors including therapeutics that addresses autoimmune, inflammatory diseases, cancer, diabetes, Alzheimer’s disease, pulmonary devices and cardiac devices.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: